Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
Phase 2RecruitingInterest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Peripheral T-Cell Lymphoma
Conditions
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Trial Timeline
Jul 1, 2024 → Jan 1, 2028
NCT ID
NCT06160843About Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
Pembrolizumab IV infusion Q3W, with daily oral Olaparib. is a phase 2 stage product being developed by Merck for Relapsed Peripheral T-Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06160843. Target conditions include Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Peripheral T-Cell Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06160843 | Phase 2 | Recruiting |
Competing Products
20 competing products in Relapsed Peripheral T-Cell Lymphoma